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Objectives: To assess the impact of variable drug response and measurement error 
on systolic blood pressure (SBP) control. 
Methods: We simulated a treat-to-target strategy for populations with different pre-
treatment SBP, whereby medications were added sequentially until measured SBP 
(mSBP) <140mmHg. Monte Carlo simulations determined variability of both drug 
response (drugeff±σdrug; 10±5mmHg base case) and measurement error (σmeas; 
10mmHg base case) of true SBP (tSBP). The primary outcome measure was the 
proportion of individuals who achieved target <140mmHg. 
Results: Decision-making based on mSBP resulted in 35.0% of individuals with initial 
tSBP 150mmHg being either inappropriately given, or inappropriately denied a 
second drug. When the simulation was run for multiple drug titrations, 
measurement error limited tSBP control for all populations tested. A strategy of drug 
titration based on a second measurement for individuals at risk of incorrect decisions 
(mSBP 120-150mmHg; σmeas 15mmHg) reduced the proportion above target from 
40.1 to 30.0% when initial tSBP 160mmHg. When the measurement variability for 
the second reading was reduced below that usually seen in clinical practice (σmeas 
5mmHg), the proportion above target decreased further to 17.4%. 
Conclusions: In this simulation, measurement error had the greatest impact on the 
proportion of individuals achieving their SBP target. Efforts to reduce this error 
through repeated-measures, alternative measurement techniques or changing 
thresholds, are promising strategies to reduce cardiovascular morbidity and 
mortality and should be investigated in clinical trials. Here we have shown that 
Monte-Carlo simulations are a useful technique to investigate the influence of 
uncertainty for different hypertension management strategies. 
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Current medical management of many common conditions involves initiating or 
changing treatment based on quantitative, semi-quantitative or qualitative 
thresholds of some measure of response to treatments. The values that define 
thresholds commonly represent either a surrogate outcome measure (e.g. blood 
pressure or spirometry) or elements of a diagnostic or symptomatic metric (e.g. 
inflammatory markers or a depression score). Typically, the focus is upon the 
average value of a measurements derived from a clinical encounter without 
attention on dispersion, yet variation or uncertainty in these values due to 
measurement error and/or physiological variation has the potential to result in 
erroneous decisions, with significant implications for efficient and effective 
healthcare delivery. As the evidence-base for personalised medicine increases, 
treatments and treatment thresholds are likely to be set according to characteristics 
of the individual and the impact of measurement error for an individual will increase 
[1]. 
 
Here we present an example of how measurement uncertainty impacts hypertension 
management, a particularly important example as hypertension is the major cause of 
death and disability worldwide [2, 3]. Hypertension is particular amenable to a 
modeling approach for a number of reasons; (i) there is a strong association between 
the measured variable (blood pressure; BP) and clinical outcomes [4, 5], (ii) 
guidelines recommend the initiation of treatment based on a threshold BP and 
subsequent drug titration to achieve a target BP [6, 7], (iii) both drug response and 
measurement variability are well-described [8-12], and (iv) most individuals require 
treatment with two or more drugs, thus providing the potential for measurement 
error to be compounded [11]. Furthermore, whilst short-, medium- and long-term BP 
variability has been associated with adverse outcomes, it is unclear to what extent 
measurement error (and hence over- or undertreatment) may contribute [13]. 
 
There is an awareness among clinicians that measurement error can result in 
incorrect treatment decisions and that approaches to minimize error are important 





measurement error can impact on the diagnosis of hypertension, with both 
inadequate device calibration and normal physiological variation contributing to 
misdiagnosis [17-19]. This study is the first simulation to investigate how 
measurement error impacts on achieving a blood pressure target for multiple drug 
titration steps and considers the impact of this on the proportion of individual 
achieving BP control. 
  
Methods  
We used a Monte Carlo simulation to investigate the impact of drug response and 
measurement variability on treatment outcomes for populations of hypertensive 
individuals. Monte Carlo simulations are powerful techniques based on 
mathematical models that describe the behavior of a system over time in response 
to stochastic (or random) variability of input parameters [20, 21]. Monte Carlo 
simulations are widely used in Astrophysics and other physical sciences where 
understanding the uncertainty arising from measurement error plays an important 
part in interpreting data[22, 23] 
 
Key parameters in our model were the true systolic BP (tSBP; a hypothetical value 
made without measurement error or physiological variability) and measured SBP 
(mSBP) which is a value obtained by the observer and includes varying degrees of 
error. Each mSBP value represented the outcome of a clinical encounter, for 
example, the mean of multiple office BP readings or ambulatory blood pressure 
measurement. We focused on SBP due to its predictive validity with outcomes, and 
recent focus in major treat-to-target studies [3, 24-27]. 
 
Observed BP variation arises from the sum of measurement error and physiological 
variation (characterised by the standard deviation of repeated measurements over 
time, σmeas), and by the variation in response to a drug (σdrug). Total variance can 
therefore be described as follows:  
σtot2 = σmeas2 + σdrug2 
Values for these parameters and the mean response to drug treatment (drugeff) were 





their effects [8-12]. Base case parameters were as follows: σmeas 10 mmHg, drugeff 10 
mmHg and σdrug 5 mmHg. 
 
Populations entered the simulation with one of three pre-treatment (initial) tSBPs: 
150, 160 or 170 mmHg. Individuals then all received a single drug with response 
drugeff±σdrug and underwent BP measurement with variation σmeas. Those with mSBP 
<140 mmHg then exited the simulation and received no further drugs, as to the 
observer they appeared to have achieved target. For those with mSBP ≥140 mmHg 
(irrespective of tSBP) they progressed to Step 2 and received another drug. This 
process of drug titration continued for each individual until their mSBP <140 mmHg. 
The number of steps for each individual represents the number of drugs received.  
 
The statistical outputs from this simulation were descriptive and considered the 
proportion of individuals who achieved SBP target (<140 mmHg) according to UK 
guidelines [27]. Undertreated was defined as tSBP ≥140 mmHg, controlled as tSBP 
120-139 mmHg, and overtreated as tSBP <120 mmHg. 
 
Results 
The typical expected distribution of tSBP and mSBP for our virtual population in 
response to a single antihypertensive titration is shown in Figure 1. In this example, 
for an initial tSBP 150 mmHg, the use of a drug with drugeff 10 mmHg and σdrug 5 
mmHg results in a mean tSBP 140 mmHg. As drug effect is normally distributed in 
our simulation, the tSBP of the population will be evenly distributed. The mean of 
mSBP values obtained by an observer will also be 140mmHg and normally 
distributed. However, the range of mSBP values is much wider than that for tSBP, 
with approximately 4% appearing to be ‘super responders’ with mSBP <120 mmHg. 
In reality, <0.001% of the simulated population have tSBP <120 mmHg. The use of a 
single mSBP reading to determine response to a single drug titration resulted in 
35.0% of the population either being inappropriately given, or inappropriately 







The relative effects of the input parameters on the proportion of individuals who 
appear to achieve target (mSBP <140 mmHg) are presented in Figure 2. Variation in 
drugeff had the largest impact on this simulation with the effect greatest at higher 
initial tSBP. Where initial tSBP was 170 mmHg, mSBP <140 mmHg was achieved in 
<20% for three drugs when drug response was 5±5 mmHg, compared to >90% when 
drug response was 15±5 mmHg. Variation in measurement (σmeas) had no effect on 
the maximal proportion achieving the mSBP target, since this error is not apparent to 
the observer. With multiple titration steps and at higher initial tSBP, we found an 
inverse relationship between measurement error and the proportion achieving 
mSBP <140 mmHg (Table 1). 
 
The relative effects of the input parameters on the proportion of individuals who 
achieved target (tSBP <140 mmHg) are presented in Figure 3. Initial tSBP, 
measurement error and drug response all influenced the proportion of the 
population who would achieve target should the simulation be run infinitum. 
Measurement error accounted for a difference of almost 30% (σmeas 5 versus 15 
mmHg) at initial tSBP 170 mmHg, compared to <10% at 150 mmHg. When 
measurement error was reduced to below that achieved in clinical practice (σmeas 5 
mmHg) the proportion who failed to achieve tSBP <140 mmHg remained high at 
approximately 30% for initial tSBP 170 mmHg. The proportion who failed to achieve 
control on three drugs is shown in Table 1. 
 
Drug response influenced both the number of steps required to achieve tSBP <140 
mmHg and the maximal proportion of the population who achieved the target. 
Where drug response was low (drugeff 5 mmHg), for an initial tSBP 170 mmHg 
approximately 40% achieved target after nine steps (a hypothetical treatment 
outcome), compared to approximately 75% where drug response was high (drugeff 
15 mmHg) (Figure 3). Variation in drug response (σdrug) also influenced the 







Due to the impact of measurement error on achieving target tSBP we next 
considered how repeated sets of readings might mitigate this. In the first instance 
we simulated a second, independent measurement at each step when mSBP 120-
150 mmHg. The second measurement in this ‘at risk population’ was then used to 
determine the outcome (i.e. addition of another drug or exit simulation) for that 
individual. Figure 4 shows that when the first and second measurements had the 
same error (σmeas 15 mmHg) there was an increase in the proportion of individuals 
with controlled tSBP (49.9% versus 60.8% for initial tSBP 170 mmHg) and a decrease 
in individuals with tSBP ≥140 mmHg across the range of initial tSBP. When a method 
of SBP measurement with a lower measurement error was used for the second 
measurement (σmeas 5 mmHg), the proportion of individuals with controlled tSBP 




The results of our simulations indicate that a large proportion of hypertensive 
individuals in whom SBP is thought to be at target following an initial drug titration, 
are in fact over- or undertreated. These individuals remain at either an increased risk 
of cardiovascular events or have an increased risk of side-effects from excessive 
medication. For example, in individuals with stage two hypertension <65% are 
controlled to within the target window (tSBP 120-139 mmHg) when clinically 
relevant base case parameters are input to the model. 
 
The model enabled us to interrogate which parameters have the greatest influence 
on both the number of drugs required to achieve tSBP control, and the proportion of 
individuals in whom control is actually achieved. Several important findings have 
emerged. Firstly, the mean drug response (drugeff) and/or standard deviation of this 
response (σdrug) principally influences the number of titration steps required to 
achieve mSBP <140 mmHg, rather than define the upper limit. Where the number of 
titration steps are unlimited (a hypothetical scenario), all individuals will eventually 
achieve mSBP <140 mmHg. However, each titration step provides an opportunity for 





for this reason that the proportion of individuals achieving target was lower when 
drugeff was reduced. 
 
Secondly, the variation in SBP measurement (σmeas) had no effect on the maximal 
proportion achieving mSBP <140 mmHg as the clinician is blinded to measurement 
error. However, a large effect was observed once tSBP values were analysed, with a 
lower proportion achieving tSBP <140 mmHg at higher initial tSBPs. Again, this 
represents the number of titration steps and thus the number of opportunities for 
measurement error. In our simulation, it is measurement error that determines most 
of the misclassification where individuals are thought to be controlled based on 
mSBP, but tSBP lies outside of the target window.  
 
Thirdly, the proportion of individuals misclassified can be reduced by an 
independent, second measurement when mSBP lies within a range that is ‘at risk’ 
from measurement error. The proportion misclassified was reduced further when 
the second measurement had lower variation than the first.  
 
The composite of our analyses demonstrate that an individual is most likely to have 
their SBP misclassified if they have a high initial tSBP, receive drugs of low efficacy 
(or suboptimal adherence), and have titration decisions based on a single SBP 
measurement with high variability. The model allows consideration of remedial 
measures to reduce the number of subjects misclassified. Options to reduce 
measurement error include the use of single measurement events with increased 
precision, or repeated measurements that are averaged over longer periods (e.g. 
oscillometric home BP monitoring or the use of wearable technology). Such an 
approach could be applied selectively to individuals with measurements close to 
threshold values to reduce the measurement burden, or to those who exhibit high 
variability to improve accuracy. Interestingly, the simulation suggests that a small 
improvement in measurement error (10 versus 15 mmHg) will have negligible impact 
on misclassification, and that an error level not currently achieved with any clinical 






However even with an accuracy greater than that usually achieved in clinical 
practice, a substantial proportion of individuals will still be misclassified and receive 
suboptimal management. An alternative approach would be to recognise that as a 
high proportion of individuals are undertreated due to misclassification, the target 
window could be lowered to reduce this number. This would result in fewer 
individuals with uncontrolled BP but a larger number with relatively low BP. Whether 
a low BP might be associated with increased morbidity and/or mortality is uncertain 
and such a strategy would have to be formally tested in clinical trials.  The challenge 
of balancing SBP targets with measurement method can be observed in the varying 
response by guideline committees to the results from the Systolic Blood Pressure 
Intervention Trial (SPRINT) [1, 6, 7, 26]. The SBP target selected for this simulation is 
consistent with UK primary prevention guidelines, but the findings are applicable to 
alternative targets and healthcare systems [27]. 
 
It is important to stress that the simulation exercise presented here is primarily for 
illustrative purposes since there are several assumptions and simplifications inherent 
to the model. The simulation is designed to investigate the number of treatment 
steps required to achieve mSBP <140 mmHg and so does not consider options for 
antihypertensive de-escalation as a response to either medication side-effects or 
overtreatment. The limited time horizon does not consider long-term SBP control. 
However, the proportion of individuals requiring three of more drugs to achieve 
mSBP <140 mmHg with clinically relevant parameters, corresponds to the prevalence 
of resistant hypertension both globally and in the UK [28, 29]. The main findings of 
this study would remain true if a more sophisticated simulation was used whereby 
drug response varied depending on SBP and the number of titrations [11]. 
 
The strength of the present simulation is that it allows the exploration of various 
management scenarios as a function of the burden of achieving more accurate 
measurements. Such an approach could inform the best strategies to be tested in 
clinical trials and provide more accurate data for health economic analyses. A full 
health economics analysis would require quantification of the relative burden of 





hypertension. Modern technology, such as a wearable wrist monitor, if sufficiently 
free from systematic bias, could potentially improve estimations of tSBP through the 
capacity to take high numbers of BP readings which would be sampled from the full 
range of potential measurement error. Such an approach would place little or no 
burden on patients or healthcare staff and could have a major impact on 
hypertension control. 
 
Our approach to simulating uncertainty can also be applied to questions which have 
either not been fully addressed in clinical trials or for where there remains 
uncertainty in interpretation of the evidence. One prominent example is the use of 
initial dual antihypertensive therapy which is recommended by both European and 
US guidelines [6, 7]. In contrast, the recent UK guidelines were unable to recommend 
this approach due to a lack of cardiovascular outcome data [27]. By combining 
simulated tSBP data with a cardiovascular outcome model (in which benefit is 
proportion to SBP reduction [11]) it may be possible to add clarity to the issue. 
Furthermore, such an approach could be extended to situations which have not been 
addressed in cardiovascular outcome studies such as initial triple antihypertensive 
therapy, decision making based on repeated measures, combinations of half-
dose/full-dose antihypertensives or novel polypill formulations. 
 
In conclusion, Monte Carlo simulations have identified measurement error as the 
major determinant for individuals trying to achieve blood pressure control during 
initial medication titration. Strategies to reduce measurement error should be tested 
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Table 1: The impact of measurement error (σmeas) on achieving target blood pressure 
for individuals taking three antihypertensive medications. 
 Initial tSBP  
150 mmHg 
Initial tSBP  
160 mmHg 






















5 1.2% 15.1% 13.2% 27.1% 48.3% 56.0% 
10 1.8% 20.4% 13.3% 39.6% 42.2% 69.2% 
15 2.8% 22.5% 13.0% 46.7% 35.4% 68.5% 
Simulation parameters: drugeff 10 mmHg; σdrug 5 mmHg; σmeas 5-15 mmHg. 











Figure 1: Distribution of (A) true systolic blood pressure (tSBP) and (B) measured 
systolic blood pressure (mSBP) after a single treatment step. Simulation conducted 
with an initial tSBP 150 mmHg, drug response (drugeff±σdrug) 10±5 mmHg and 






Figure 2: Proportion of individuals achieving a measured systolic blood pressure 
(mSBP) <140 mmHg with increasing drug titration.  
Simulation inputs were varied based on initial true SBP (top of figure), drug response 






Figure 3: Proportion of individuals achieving a true systolic blood pressure (tSBP) 
<140 mmHg with increasing drug titration.  
tSBP values calculated once mSBP <140 mmHg and subject had exited the 
simulation. Simulation inputs were varied based on initial t SBP (at top of figure), 






Figure 4: Classification of true systolic blood pressure (tSBP) for individuals exiting 
the simulation based on (A) single mSBP, (B) repeated measurement when first 
mSBP 120-150 mmHg, and (C) when second measurement is repeated with greater 
precision (σmeas 5 mmHg) when first mSBP 120-150 mmHg. Analyses performed for 
different initial tSBP (top of figure). The response to each titration step was fixed at 
10±5 mmHg (drugeff ± σdrug). 
 
